Last A$0.01 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 9:44 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

agenix ltd (AGX) Snapshot

Open
A$0.01
Previous Close
A$0.01
Day High
A$0.01
Day Low
A$0.01
52 Week High
01/14/14 - A$0.04
52 Week Low
06/30/14 - A$0.01
Market Cap
1.7M
Average Volume 10 Days
32.2K
EPS TTM
A$-0.0062
Shares Outstanding
130.9M
EX-Date
11/16/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENIX LTD (AGX)

Related News

No related news articles were found.

agenix ltd (AGX) Related Businessweek News

No Related Businessweek News Found

agenix ltd (AGX) Details

Agenix Limited, a biotechnology company, provides next generation drugs and diagnostics primarily in Australia and the People’s Republic of China. The company operates through AGX-1009, ThromboView, and DiagnostIQ segments. The AGX-1009 segment is involved in developing an anti-viral drug for the treatment of hepatitis B patients, which is a patented novel targeted prodrug analog of an existing compound, Tenofovir and has completed pre-clinical trials. The ThromboView segment develops a monoclonal antibody related to the detection of blood clots. The DiagnostIQ segment offers DiagnostIQ, a rapid point-of-care diagnostic technology for a various human health applications. Agenix Limited is based in Melbourne, Australia.

agenix ltd (AGX) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: A$185.4K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$150.0K
Manager of New Drugs - China
Total Annual Compensation: A$32.3K
Compensation as of Fiscal Year 2013.

agenix ltd (AGX) Key Developments

Agenix Ltd. expected to report Fiscal Year 2014 results on August 29, 2014. This event was calculated by Capital IQ (Created on May 22, 2014).

Agenix Ltd. expected to report Fiscal Year 2014 results on August 29, 2014. This event was calculated by Capital IQ (Created on May 22, 2014).

Agenix Ltd. Presents at Australia Biotech Invest 2013, Oct-29-2013 12:08 PM

Agenix Ltd. Presents at Australia Biotech Invest 2013, Oct-29-2013 12:08 PM. Venue: Melbourne Convention & Exhibition Centre, 1 Convention Centre Place, South Wharf, Melbourne, 3006, Victoria, Australia. Speakers: Nicholas Weston, Executive Chairman and Chief Executive Officer.

Agenix Ltd., Annual General Meeting, Oct 31, 2013

Agenix Ltd., Annual General Meeting, Oct 31, 2013., at 11:30 AUS Eastern Standard Time. Location: BDO Brisbane Boardroom, Level 10. Agenda: To receive the financial report and the reports of the Directors and Auditors for the year ended June 30, 2013; to adopt remuneration report; to consider election of Mr. Craig Chapman as a Director; to consider re-election of Mr. Christopher McNamara as a Director; to issue 200,000 ordinary shares to BFC Group Limited; to issue up to 800,000 ordinary shares to BFC Group Limited; to consider approval of issue of securities to Tyrian Diagnostics Limited; to consider additional share placement capacity; and to deal with any other business which may generally be brought forward.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGX:AU A$0.01 AUD 0.00

AGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGX.
View Industry Companies
 

Industry Analysis

AGX

Industry Average

Valuation AGX Industry Range
No financial data is available for AGX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENIX LTD, please visit www.agenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.